Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Five Prime Thera (FPRX)

37.76   -0.24 (-0.63%) 03-07 04:11
Open: 37.87 Pre. Close: 38
High: 37.95 Low: 37.7
Volume: 11,219,125 Market Cap: 1,735M
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 37.998 - 38.183 38.183 - 38.365
Low: 37.146 - 37.382 37.382 - 37.614
Close: 37.325 - 37.697 37.697 - 38.065

Technical analysis

as of: 2021-03-05 5:08:12 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 44.59     One year: 52.09
Support: Support1: 24.18    Support2: 15.52
Resistance: Resistance1: 38.18    Resistance2: 44.59
Pivot: 24.45
Moving Average: MA(5): 28.55     MA(20): 23.38
MA(100): 16.07     MA(250): 9.07
MACD: MACD(12,26): 3.40     Signal(9): 2.06
Stochastic oscillator: %K(14,3): 75.92     %D(3): 60.04
RSI: RSI(14): 78.74
52-week: High: 38.18  Low: 1.75  Change(%): 1040.8
Average Vol(K): 3-Month: 168202  10-Days: 546000

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
FPRX has closed above the upper band by 10.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 182.3% wider than normal. The large width of the bands suggest high volatility as compared to FPRX's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Sat, 06 Mar 2021
Roth Capital Lowers Five Prime Therapeutics (NASDAQ:FPRX) to Neutral - MarketBeat

Fri, 05 Mar 2021
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Five Prime Therapeutics, Inc. - FPRX - PRNewswire

Fri, 05 Mar 2021
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Five Prime Therapeutics, Inc. - Investing News Network

Fri, 05 Mar 2021
Five Prime Therapeutics (FPRX) Stock Jumps 78.7%: Will It Continue to Soar? - Yahoo Finance

Thu, 04 Mar 2021
SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc. - Yahoo Finance

Thu, 04 Mar 2021
Amgen (AMGN) To Acquire Five Prime Therapeutics (FPRX) For $1.9 Billion in Cash, $38/share - StreetInsider.com

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 38
Shares Float (M) 36
% Held by Insiders 3.19
% Held by Institutions 47.10
Shares Short (K) 2,250
Shares Short P. Month (K) 1,140

Stock Financials

EPS -2.680
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.670
Profit Margin
Operating Margin -513.07
Return on Assets (ttm) -26.2
Return on Equity (ttm) -69.3
Qtrly Rev. Growth -31.4
Gross Profit (p.s.) -2.444
Sales Per Share 0.450
EBITDA (p.s.) -2.196
Qtrly Earnings Growth
Operating Cash Flow (M) -81
Levered Free Cash Flow (M) -45

Stock Valuations

PE Ratio -14.09
PEG Ratio
Price to Book value 14.14
Price to Sales 84.00
Price to Cash Flow -17.73

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.